Clinical Trials /

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

NCT02724579

Description:

This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment.

Related Conditions:
  • Medulloblastoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
  • Official Title: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Clinical Trial IDs

  • ORG STUDY ID: ACNS1422
  • SECONDARY ID: NCI-2016-00150
  • SECONDARY ID: ACNS1422
  • SECONDARY ID: ACNS1422
  • SECONDARY ID: ACNS1422
  • SECONDARY ID: U10CA180886
  • NCT ID: NCT02724579

Conditions

  • CTNNB1 Gene Mutation
  • Medulloblastoma
  • Wnt Positive

Interventions

DrugSynonymsArms
CisplatinAbiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, PlatosinTreatment (reduced radiation therapy and chemotherapy)
Cyclophosphamide(-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719Treatment (reduced radiation therapy and chemotherapy)
Lomustine1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, Belustin, Belustine, CCNU, Cecenu, CeeNU, Chloroethylcyclohexylnitrosourea, Citostal, Gleostine, Lomeblastin, Lomustinum, Lucostin, Lucostine, N-(2-Chloroethyl)-N''-cyclohexyl-N-nitrosourea, Prava, RB-1509, WR-139017Treatment (reduced radiation therapy and chemotherapy)
VincristineLEUROCRISTINE, VCR, VincrystineTreatment (reduced radiation therapy and chemotherapy)
Vincristine SulfateKyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfateTreatment (reduced radiation therapy and chemotherapy)

Purpose

This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment.

Detailed Description

      PRIMARY OBJECTIVES:

      I. To estimate the progression-free survival (PFS) of children >= 3 years of age with
      wingless-type MMTV integration site family (WNT)-driven average-risk medulloblastoma using
      reduced craniospinal radiotherapy (CSI) (18 Gray [Gy]) with a limited target volume boost to
      the tumor bed of 36 Gy for a total of 54 Gy and reduced chemotherapy approach (no vincristine
      [vincristine sulfate] during radiotherapy and reduced-dose maintenance chemotherapy) and to
      monitor the PFS for early evidence that the outcome is unacceptable.

      SECONDARY OBJECTIVES:

      I. To prospectively test the hypothesis that deoxyribonucleic acid (DNA) methylation
      profiling will accurately classify WNT-driven medulloblastoma.

      II. To prospectively evaluate and longitudinally model the cognitive, social, emotional,
      behavioral, and quality of life (QoL) functioning of children who are treated with reduced
      CSI (18 Gy) with a limited target volume boost to the tumor bed (to a total of 54 Gy) and
      reduced chemotherapy (reduced cisplatin, vincristine, and lomustine [CCNU]).

      EXPLORATORY OBJECTIVES:

      I. To explore whether DNA methylation profiling of medulloblastoma samples will result in a
      predictive classification scheme for the Sonic Hedgehog (SHH), Group 3, and Group 4
      medulloblastoma subgroups according to the Heidelberg classifier.

      II. To describe the audiologic and endocrinologic toxicities, as well as peripheral
      neuropathy, in children treated with reduced CSI (18 Gy) with a limited target volume boost
      to the tumor bed (to a total of 54 Gy) and reduced cisplatin and vincristine chemotherapy.

      OUTLINE:

      RADIATION THERAPY: Beginning 4-5 weeks after surgery, patients undergo craniospinal radiation
      therapy 5 days a week for 6 weeks.

      MAITENANCE THERAPY (WEEKS 1, 3, 5, and 7): Beginning 4-6 weeks after completion of radiation
      therapy patients receive lomustine orally (PO) on day 1, vincristine sulfate intravenously
      (IV) over 1 minute or via minibag on days 1, 8, and 15, and cisplatin IV over 6 hours on day
      1. Treatment repeats every 42 days in the absence of disease progression or unacceptable
      toxicity.

      MAINTENANCE THERAPY (WEEKS 2, 4, AND 6): Patients receive cyclophosphamide IV over 30-60
      minutes on days 1 and 2, mesna IV over 15-30 minutes on days 1 and 2, and vincristine sulfate
      IV over 1 minute or via minibag on days 1 and 8. Treatment repeats every 28 days in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 2 years,
      every 6 months for 2 years, and then annually for 6 years.
    

Trial Arms

NameTypeDescriptionInterventions
Treatment (reduced radiation therapy and chemotherapy)ExperimentalRADIATION THERAPY: Beginning 4-5 weeks after surgery, patients undergo craniospinal radiation therapy 5 days a week for 6 weeks. MAITENANCE THERAPY (WEEKS 1, 3, 5, and 7): Beginning 4-6 weeks after completion of radiation therapy patients receive lomustine PO on day 1, vincristine sulfate IV over 1 minute or via minibag on days 1, 8, and 15, and cisplatin IV over 6 hours on day 1. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY (WEEKS 2, 4, AND 6): Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 2, mesna IV over 15-30 minutes on days 1 and 2, and vincristine sulfate IV over 1 minute or via minibag on days 1 and 8. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
  • Cisplatin
  • Cyclophosphamide
  • Lomustine
  • Vincristine
  • Vincristine Sulfate

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must be newly diagnosed and have:

               -  Eligibility confirmed by rapid central pathology and molecular screening review
                  on APEC14B1:

                    -  Classical histologic type (non LC/A) WNT medulloblastoma

                    -  Positive nuclear beta-catenin by immunohistochemistry (IHC)

                    -  Positive for CTNNB1 mutation

                    -  Negative for MYC and MYCN by fluorescence in situ hybridization (FISH)

          -  Patient must have negative lumbar cerebrospinal fluid (CSF) cytology

               -  Note: CSF cytology for staging should be performed no sooner than 14 days post
                  operatively to avoid false positive CSF; ideally, CSF should be obtained between
                  day 14 and day 21 to allow for final staging status before enrollment onto the
                  study; patients with positive CSF cytology obtained 0 to 14 days after surgery
                  should have cytology repeated to determine eligibility and final CSF status;
                  patients with negative CSF cytology from lumbar puncture obtained 0 to 14 days
                  after surgery do not need cytology repeated; patients with negative CSF cytology
                  from lumbar puncture obtained prior to surgery do not need cytology repeated
                  post-operatively

          -  Patients must have eligibility confirmed by Rapid Central Imaging Review on APEC14B1;
             patients must have =< 1.5 cm^2 maximal cross-sectional area of residual tumor; whole
             brain magnetic resonance imaging (MRI) with and without gadolinium and spine MRI with
             gadolinium must be performed

          -  Patients must be enrolled, and protocol therapy must be projected to begin, no later
             than 36 days after definitive diagnostic surgery (day 0)

          -  Peripheral absolute neutrophil count (ANC) >= 1000/uL

          -  Platelet count >= 100,000/uL (transfusion independent)

          -  Hemoglobin >= 10.0 g/dL (may receive red blood cell [RBC] transfusions)

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
             mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

               -  3 to < 6 years of age: maximum (max) serum creatinine 0.8 mg/dL (males and
                  females)

               -  6 to < 10 years of age: max serum creatinine 1 mg/dL (males and females)

               -  10 to < 13 years of age: max serum creatinine 1.2 mg/dL (males and females)

               -  13 to < 16 years of age: max serum creatinine 1.5 md/dL (males) and 1.4 md/dL
                  (females)

               -  >= 16 years of age: max serum creatinine 1.7 mg/dL (males) and 1.4 mg/dL
                  (females)

                    -  The threshold creatinine values were derived from the Schwartz formula for
                       estimating GFR utilizing child length and stature data published by the
                       Centers for Disease Control and Prevention (CDC)

          -  Total or direct bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

          -  Serum glutamate pyruvate (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L (3x ULN);
             for the purpose of this study, the ULN for SGPT is 45 U/L

          -  Central nervous system function defined as:

               -  Patients with seizure disorder may be enrolled if on anticonvulsants and well
                  controlled

               -  Patients must not be in status epilepticus, a coma or on assisted ventilation at
                  the time of study enrollment

          -  Patients must have receptive and expressive language skills in English, French, or
             Spanish to complete the QoL and neurocognitive assessments; if a patient meets these
             criteria but the parent/guardian speaks a language other than English, French, or
             Spanish, the patient may still be enrolled and tested, and the parent-report measures
             should be omitted

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent; assent, when appropriate, will be obtained according to institutional
             guidelines

          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute
             (NCI) requirements for human studies must be met

        Exclusion Criteria:

          -  Patients with metastatic disease by either MRI evaluation (brain and spine) or lumbar
             CSF cytology are not eligible; patients who are unable to undergo a lumbar puncture
             for assessment of CSF cytology are ineligible

          -  Patients must not have received any prior radiation therapy or chemotherapy
             (tumor-directed therapy) other than surgical intervention and/or corticosteroids

          -  Pregnancy and Breast Feeding

               -  Female patients who are pregnant are ineligible due to risks of fetal and
                  teratogenic adverse events as seen in animal/human studies

               -  Lactating females are not eligible unless they have agreed not to breastfeed
                  their infants

               -  Female patients of childbearing potential are not eligible unless a negative
                  pregnancy test result has been obtained

               -  Sexually active patients of reproductive potential are not eligible unless they
                  have agreed to use an effective contraceptive method for the duration of their
                  study participation

          -  Patients with a history of moderate to profound intellectual disability (i.e.,
             intelligence quotient [Q)]=< 55) are not eligible for enrollment; PLEASE NOTE:
             Children with a prior history of attention deficit hyperactivity disorder (ADHD) or a
             specific learning disability (e.g., dyslexia) are eligible for this study
      
Maximum Eligible Age:21 Years
Minimum Eligible Age:3 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Progression-free survival (PFS)
Time Frame:From the initiation of protocol treatment to the occurrence of any of the following events: disease progression or disease recurrence or death from any cause, assessed up to 10 years
Safety Issue:
Description:PFS along with the confidence intervals will be estimated using the Kaplan-Meier method. PFS will also be reported based on central radiology review.

Secondary Outcome Measures

Measure:Deoxyribonucleic acid (DNA) methylation profiling as real-time classification of WNT-driven medulloblastoma
Time Frame:Within 32 days of definitive surgery
Safety Issue:
Description:Results will be compared to the results of the molecular screening tests. The sensitivity and specificity comparison between DNA methylation arrays and the standard methods (molecular screening tests for WNT using immunohistochemistry [IHC] and CTNNB1 sequencing) will be performed using McNemar?s test.
Measure:Change in neurocognitive function (cognitive, social, emotional and behavioral) according to Children Oncology Group Standard Neuropsychological Battery
Time Frame:Baseline to up to 60 months post-diagnosis
Safety Issue:
Description:Neurocognitive function will be measured at 9, 30 and 60 months post diagnosis and will be compared with the neurocognitive outcomes from an age and gender matched ACNS0331 cohort to the WNT patients treated on ACNS1422. Data for all assessments will be available as standardized t-scores. The change over time for each component of the neuropsychological testing will be estimated using the Generalized Estimating Equation (GEE) approach, with the standardized t-scores as the dependent variable and the assessment times as a covariate. Within the ACNS1422 cohort GEE models will also be used to explore associations of changes over time with factors such as gender, age at initiation of radiation therapy, tumor location, number of surgical interventions, etc.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Children's Oncology Group

Last Updated